2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1729

Predictors and Clinical Factors Associated with Change in Spinal Inflammation Assessed on MRI over 2 Years: Data from Tasmanian Ankylosing Spondylitis Study
Abstract Number: 503

Predictors for Attaining Remission at Two Consecutive Visits in Newly Diagnosed Early RA Patients
Abstract Number: 2395

Predictors of and Longitudinal Factors Associated with Change in Pain, Stiffness and Physical Function over 8 Years in a Midlife Cohort with a Low Prevalence of Knee Osteoarthritis
Abstract Number: 1708

Predictors of Depression Severity in Ankylosing Spondylitis
Abstract Number: 3187

Predictors of Disease Relapse and Recapture of Remission Following Relapse in an Ontario Rheumatoid Arthritis Population
Abstract Number: 2870

Predictors of Early Minimal Disease Activity in Psa Patients Treated with Anti-TNF in a Real-World Registry
Abstract Number: 1528

Predictors of Employment, Work Productivity Loss, Activity Impairment, and Regaining Employment in Latinos with Rheumatoid Arthritis in the United States
Abstract Number: 2083

Predictors of Health Perceptions Among Women with Lupus
Abstract Number: 2233

Predictors of Imminent Fracture Risk in Women Aged >=65 Years with Osteoporosis
Abstract Number: 572

Predictors of Long-Term Retention of Infliximab and Golimumab in Rheumatoid Arthritis: An Analysis from a Prospective, Observational Registry
Abstract Number: 3149

Predictors of Longitudinal Quality of Life Impact in Pediatric Localized Scleroderma
Abstract Number: 61

Predictors of Mortality Among Patients with Sarcoidosis: A Population-Based Study
Abstract Number: 2897

Predictors of Organ Damage Progression and Impact on Health-Related Quality of Life in Systemic Lupus Erythematosus
Abstract Number: 455

Predictors of Real-World Treatment Sustainability in RA Patients Treated with Abatacept in Canada: Implications for Routine Care
Abstract Number: 859

Predictors of Renal Histopathology in Antineutrophil Cytoplasmic Antibody Associated Glomerulonephritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].